|Biotech partner:||Basilea Pharmaceutical (Switzerland)|
|Pharma Partner:||Almirall (Spain)|
|Type of agreement:||* commercialization/ distribution
|Disease area:||severe chronic hand eczema|
|Development phase:||To date, Toctino® is launched in Denmark, France, Germany, Switzerland and the United Kingdom for the treatment of severe chronic hand eczema. The drug is approved in 15 additional European countries as well as in Canada and has been recommended for approval in seven further European countries.|
|Nature of the agreement:||Almirall has announced an international exclusive distribution agreement to commercialize Basilea’s Toctino®, a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, in Austria, Belgium, Czech Republic, Italy, Luxembourg, Mexico, the Netherlands, Poland, Portugal, Slovakia and Spain.
Toctino® is already approved in all the countries under the scope of this agreement except in Czech Republic and Mexico. The product has been granted pricing and reimbursement in Italy and Austria where, launch preparations are being initiated. A sequential roll-out to European countries is foreseen during the second half of 2010 and 2011.
|Financial terms of the agreement:||Under the terms of the agreement, Almirall will make an upfront and milestone payments related to the launch of Toctino® in two key markets of the territory of up to € 16 million, and will pay future milestones related to pre-specified sales achievements.